GlassScriptPhysician profile
Terry O Harrison
NPI 1063494193
$9,001.14
in general payments reported to CMS, 2019-2025
45 companies · $859 in 2025
The $859 reported for 2025 was more than what 90% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,566 · 2020: $1,483 · 2021: $1,781 · 2022: $1,046 · 2023: $1,080 · 2024: $1,187 · 2025: $859.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,992 · Education: $132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,992.49 |
| Education | $132.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,178.94 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $1,014.35 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $902.98 | 2019-2025 | |
| Amgen INC. | $627.50 | 2019-2023 | Evenity, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $486.49 | 2019-2025 | Jardiance |
| Abbvie INC. | $369.82 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $346.53 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Sanofi-Aventis U.S. LLC | $260.19 | 2019-2023 | |
| Phathom Pharmaceuticals, INC. | $248.04 | 2024-2025 | Voquezna |
| Daiichi Sankyo INC. | $244.72 | 2020-2024 | Injectafer |
| Amarin Pharma, INC. | $228.39 | 2020-2021 | |
| Kls-Martin L.P. | $213.28 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $208.79 | 2022-2024 | |
| Glaxosmithkline, LLC. | $202.67 | 2019-2023 | Trelegy Ellipta, Shingrix |
| Astellas Pharma US INC | $193.23 | 2020-2023 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $173.40 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $168.39 | 2020-2024 | Linzess |
| Novartis Pharmaceuticals Corporation | $151.95 | 2019-2024 | |
| Mylan Specialty L.P. | $148.82 | 2019-2023 | Yupelri |
| Lilly USA, LLC | $142.29 | 2019-2024 | Mounjaro, Zepbound, Trulicity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $133.23 | 2020-2023 | Xifaxan |
| Eisai INC. | $132.78 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $121.32 | 2022-2024 | Rexulti |
| Corcept Therapeutics | $115.77 | 2020-2022 | |
| Exact Sciences Corporation | $109.57 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Dexcom, INC. | $106.31 | 2021-2024 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $98.73 | 2020-2024 | Nexletol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $93.18 | 2024-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $86.26 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $71.64 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $64.12 | 2019-2024 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $55.32 | 2019-2024 | Eliquis |
| Abbott Laboratories | $39.26 | 2024 | Freestyle Libre 3 |
| Insmed, INC. | $32.48 | 2025 | Arikayce |
| Lundbeck LLC | $31.57 | 2022-2025 | Rexulti |
| Evoke Pharma, INC. | $30.56 | 2023 | Gimoti |
| Xeris Pharmaceuticals, INC. | $27.86 | 2021 | |
| Horizon Therapeutics Plc | $27.53 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $24.81 | 2022 | |
| Seqirus USA INC | $19.75 | 2021 | |
| Vanda Pharmaceuticals INC. | $17.44 | 2020 | |
| Baxter Healthcare | $14.88 | 2023 | Hillrom - Life 2000 Ventilation System |
| Teva Pharmaceuticals USA, INC. | $12.86 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $11.76 | 2021 | |
| Biodelivery Sciences International, INC. | $11.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terry Harrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.